Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Date:11/17/2009

cancers is currently underway in the U.S. Interim results from both the U.K. and the U.S. studies formed the basis for the Company's decision to conduct a Phase III pivotal program looking at REOLYSIN in combination with carboplatin/paclitaxel in this patient population. The Company has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of the Phase III trial.

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
2. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
6. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
7. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
9. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
10. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
11. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... of scientific research products, recently opened an online ... comprehensive cell culture product lines developed and manufactured ... its online store include Biological Industries’ Nutristem® serum-free, ... and human embryonic stem cell (hESC) culture. ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... ALTO, Calif., July 8 Telik, Inc.,(Nasdaq: ... in Bioorganic &,Medicinal Chemistry Letters describing a novel ... to a new treatment for diabetes.,These unique compounds ... at Telik to optimize the original lead structure ...
... distribute US-made bulk API, BATON ROUGE, ... Corporation (NYSE: ALB ), a leading ... other active pharmaceutical,ingredients (APIs), has signed a ... Ltd. As per the agreement, effective,immediately, Albemarle ...
... 8 GeneGo, Inc., the leading,systems biology tools ... has become a certified GeneGo Center of Excellence ... training and advanced,support., The W. M. Keck ... largest biotechnology laboratories of its kind in academia, ...
Cached Biology Technology:Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 populations ... the globe dropped 52 percent, says the 2014 ... Fund (WWF). This biodiversity loss occurs disproportionately in ... of high-income countries. , In addition to the ... point to other warning signs about the overall ...
(Date:9/29/2014)... According to a new Food and Brand Lab pilot ... increase participation in the National School Lunch Program (NSLP) ... by 16%! , Chefs Move to Schools (CMTS), an ... with schools in order to provide nutrition instruction to ... workers. , A CMTS event was held in an ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2Half of global wildlife lost, says new WWF report 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... blocks for next-generation computer memory has earned a University ... award. Vassiliy Lubchenko, an assistant professor of ... Alfred P. Sloan Research Fellow for his achievements and ... 54 colleges and universities in the United States and ...
... laboratory research using magnetically guided nanoparticles to deliver drugs ... has just spun off its first startup company, Vascular ... VMI, a new company formed to develop the lab ... to create a novel, greatly needed treatment for peripheral ...
... Obesity appears to impair normal muscle function ... implications for humans, according to Penn State researchers. ... accumulating excess fat and carrying excess weight," said ... in physiological genomics, Penn State College of Medicine. ...
Cached Biology News:UH chemist investigates material for next-generation computer memory 2CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research 2CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research 3Obesity creates wimpy rats 2
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
MarrowMAX Bone Marrow Medium...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: